249 related articles for article (PubMed ID: 21537084)
1. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.
Aucagne R; Droin N; Paggetti J; Lagrange B; Largeot A; Hammann A; Bataille A; Martin L; Yan KP; Fenaux P; Losson R; Solary E; Bastie JN; Delva L
J Clin Invest; 2011 Jun; 121(6):2361-70. PubMed ID: 21537084
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
[TBL] [Abstract][Full Text] [Related]
3. [TIF1γ: a tumor suppressor gene in chronic myelomonocytic leukemia].
Aucagne R; Droin N; Solary E; Bastie JN; Delva L
Med Sci (Paris); 2011; 27(8-9):696-8. PubMed ID: 21880252
[No Abstract] [Full Text] [Related]
4. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Braun T; Itzykson R; Renneville A; de Renzis B; Dreyfus F; Laribi K; Bouabdallah K; Vey N; Toma A; Recher C; Royer B; Joly B; Vekhoff A; Lafon I; Sanhes L; Meurice G; Oréar C; Preudhomme C; Gardin C; Ades L; Fontenay M; Fenaux P; Droin N; Solary E;
Blood; 2011 Oct; 118(14):3824-31. PubMed ID: 21828134
[TBL] [Abstract][Full Text] [Related]
5. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
[TBL] [Abstract][Full Text] [Related]
6. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
[TBL] [Abstract][Full Text] [Related]
7. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
9. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
10. Adult hematopoiesis is regulated by TIF1γ, a repressor of TAL1 and PU.1 transcriptional activity.
Kusy S; Gault N; Ferri F; Lewandowski D; Barroca V; Jaracz-Ros A; Losson R; Romeo PH
Cell Stem Cell; 2011 Apr; 8(4):412-25. PubMed ID: 21474105
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
Carr RM; Patnaik MM
Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
[TBL] [Abstract][Full Text] [Related]
12. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
[TBL] [Abstract][Full Text] [Related]
13. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
15. The zebrafish moonshine gene encodes transcriptional intermediary factor 1gamma, an essential regulator of hematopoiesis.
Ransom DG; Bahary N; Niss K; Traver D; Burns C; Trede NS; Paffett-Lugassy N; Saganic WJ; Lim CA; Hersey C; Zhou Y; Barut BA; Lin S; Kingsley PD; Palis J; Orkin SH; Zon LI
PLoS Biol; 2004 Aug; 2(8):E237. PubMed ID: 15314655
[TBL] [Abstract][Full Text] [Related]
16. How I treat chronic myelomonocytic leukemia.
Solary E; Itzykson R
Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK
Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336
[TBL] [Abstract][Full Text] [Related]
18. TiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes.
Bai X; Trowbridge JJ; Riley E; Lee JA; DiBiase A; Kaartinen VM; Orkin SH; Zon LI
Dev Biol; 2013 Jan; 373(2):422-30. PubMed ID: 23159334
[TBL] [Abstract][Full Text] [Related]
19. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
Merlevede J; Droin N; Qin T; Meldi K; Yoshida K; Morabito M; Chautard E; Auboeuf D; Fenaux P; Braun T; Itzykson R; de Botton S; Quesnel B; Commes T; Jourdan E; Vainchenker W; Bernard O; Pata-Merci N; Solier S; Gayevskiy V; Dinger ME; Cowley MJ; Selimoglu-Buet D; Meyer V; Artiguenave F; Deleuze JF; Preudhomme C; Stratton MR; Alexandrov LB; Padron E; Ogawa S; Koscielny S; Figueroa M; Solary E
Nat Commun; 2016 Feb; 7():10767. PubMed ID: 26908133
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
